The development of a novel dual-targeting peptide vaccine therapy in patients with resected pancreatic cancer.

Trial Profile

The development of a novel dual-targeting peptide vaccine therapy in patients with resected pancreatic cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2017

At a glance

  • Drugs OCV C01 (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 18-month results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 24 Nov 2013 Status changed from not yet recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 06 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top